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Mechanism of activation of the BNLF2a immune evasion gene of
Epstein-Barr virus by Zta
Rajaei Almohammed,† Kay Osborn, Sharada Ramasubramanyan,‡ Ijiel Barak Naranjo Perez-Fernandez, Anja Godfrey,
Erika J. Mancini and Alison J. Sinclair*
Abstract
The human gamma herpes virus Epstein–Barr virus (EBV) exploits multiple routes to evade the cellular immune response.
During the EBV lytic replication cycle, viral proteins are expressed that provide excellent targets for recognition by cytotoxic
T cells. This is countered by the viral BNLF2a gene. In B cells during latency, where BNLF2a is not expressed, we show that
its regulatory region is embedded in repressive chromatin. The expression of BNLF2a mirrors the expression of a viral lytic
cycle transcriptional regulator, Zta (BZLF1, EB1, ZEBRA), in B cells and we propose that Zta plays a role in up-regulating
BNLF2a. In cells undergoing EBV lytic replication, we identified two distinct regions of interaction of Zta with the chromatin-
associated BNLF2a promoter. We identify five potential Zta-response elements (ZREs) in the promoter that are highly
conserved between virus isolates. Zta binds to these elements in vitro and activates the expression of the BNLF2a promoter
in both epithelial and B cells. We also found redundancy amongst the ZREs. The EBV genome undergoes a biphasic DNA
methylation cycle during its infection cycle. One of the ZREs contains an integral CpG motif. We show that this can be DNA
methylated during EBV latency and that both Zta binding and promoter activation are enhanced by its methylation. In
summary, we find that the BNLF2a promoter is directly targeted by Zta and that DNA methylation within the proximal ZRE
aids activation. The implications for regulation of this key viral gene during the reactivation of EBV from latency are
discussed.
INTRODUCTION
Epstein–Barr virus (EBV) is a human gamma herpes virus
that has a lifetime association with the host and can enter
into a state of long-term latency in memory B cells [1]. Dur-
ing viral latency, most of the EBV lytic replication cycle
genes are transcriptionally silent [2–5]. A repressive chro-
matin context is considered to contribute to this, as some
EBV lytic replication cycle promoters within the EBV
genome have been shown to be associated with heterochro-
matin, polycomb-associated chromatin or DNA methyla-
tion (e.g. [6–12]). In response to differentiation signals,
EBV undergoes the lytic replication cycle in both B cells
[13] and epithelial cells [14].
The viral transcription factor Zta (BZLF1, ZEBRA, EB1) is
essential for this process [15]. Zta interacts with sequence-spe-
cific DNA elements in epigenetically repressed chromatin and
drives the activation of certain viral lytic replication cycle
genes [16, 17]. Genome-wide mapping of Zta interactions
with the viral genome revealed many further genes that are
potentially directly regulated by interaction with Zta [18, 19].
Expression of the viral gene BNLF2a occurs during the early
phase of EBV lytic cycle replication [20]. BNLF2a has an
important role in evading immune surveillance by encoding
a 60-amino acid protein that interferes with antigen presen-
tation to CD8+ cells. This is achieved through blocking the
peptide- and ATP-binding functions of transporter-associ-
ated antigen processing (TAP) [21–25]. The relevance of
BNLF2a is highlighted by the impact that a genetic knock-
out mutation of BNLF2a has on cells newly infected with
EBV and those undergoing the lytic cycle – they become
more susceptible to recognition by CD8+ T cells [22, 26].
The expression of BNLF2a mRNA and protein follows from
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Zta during EBV reactivation [3, 22], suggesting a coordi-
nated mechanism of regulation or a direct link between the
two.
Here we questioned how regulation of BNLF2a is achieved
during lytic reactivation. We present evidence that the
promoter is associated with repressive chromatin during
latency and that it can be activated through the direct inter-
action of Zta with sequence-specific Zta binding elements
(ZREs) in the promoter region. An unexpected redundancy
between multiple functional Zta binding sites was revealed
through biochemical and genetic analyses. Additionally, we
find that the proximal ZRE can be subject to DNA methyla-
tion during latency and that this leads to enhanced DNA
binding and activation by Zta. Conservation of these ele-
ments across virus isolates underscores the importance of
fail-safe mechanisms to ensure appropriate activation of
this critically important gene.
RESULTS
A repressive chromatin environment surrounds the
BNLF2a promoter during viral latency
The BNLF2a gene is not expressed during EBV latency
within B cells. We asked whether the promoter for BNLF2a
is associated with repressive chromatin: H3K9me3, a marker
of heterochromatin, or H3K27me3, a marker of polycomb
repressive complexes [27]. We undertook chromatin precip-
itation experiments from two latent Burkitt’s lymphoma
(BL) cell lines (Akata and Raji) and a tightly latent lympho-
blastoid cell line (GM2188). Precipitation with a control
non-specific antibody was used to set the baseline for the
ChIP assays. Analysis of H3K27me3 and H3K9me3 with
three EBV lytic cycle-associated loci (OriLyt, the BRLF1
promoter and the BNLF2a promoter) and two active pro-
moters (GAPHD and either a latency promoter [Qp (Akata)
or Cp (Raji and LCL)], revealed a significant enrichment of
H3K27me3 and H3K9me3 with the BNLF2a promoter for
each cell type, compared to the control antibody (P0.01)
(Fig. 1). Furthermore, the association with the BNLF2a pro-
moter was significantly increased compared to association
with two active promoters in each cell line (P0.01). The
pattern of enrichment for markers of repressive chromatin
at latency/lytic regions of EBV genomes within the three dif-
ferent cell types conforms to the general pattern seen in
other cells [7, 8, 28, 29], as do data from tightly latent LCLs
within the Encode database [30].
Zta interacts with the BNLF2a promoter in cells
The Zta transcription factor plays a central role in activating
the expression of many EBV genes [31]. Expression of both
Zta and BNLF2a is activated during EBV lytic replication [3,
22]. This prompted us to ask whether BNLF2a might be a
direct transcriptional target of Zta.
A genome-wide chromatin immunoprecipitation (ChIP)
dataset detailing the interaction of Zta with the EBV
genome in Akata cells undergoing the lytic replication cycle
(induced by stimulation with anti-IgG for 48 h) [19] was
mined (Fig. 2a, b). The relative signal for input chromatin is
compared in Fig. S1(a, b, available in the online version of
this article). In this experiment, the average size of Zta-asso-
ciated peaks was 316±244 nucleotides. The analysis identi-
fied binding sites for Zta on the EBV genome in the
BNLF2a promoter region (Fig. 2a); the signal was specific to
the Zta ChIP data track (Fig. S1). A region of the genome
2Kb distal to Orilyt, which showed low binding by Zta, was
identified as a control low binding region (Fig. 2b). To con-
firm Zta binding and to question whether a similar associa-
tion with Zta occurs in other cells, we undertook further
chromatin immunoprecipitation from two cell lineages
where EBV undergoes a lytic replication cycle: a group I BL
cell line (Akata) (induced by stimulation with a low dose of
anti-IgG for 48 h) and a spontaneously lytic lymphoblastoid
cell line (LCL#3) [32]. Both cell populations showed an
equivalent level of lytic cells as determined by intracellular
staining and FACs analysis (6–7%Zta-positive data not
shown). We identified significant enrichment of Zta at the
BNLF2a promoter compared to a region flanking OriLyt in
both cell types (P0.01) (Fig. 2c, d).
Conservation of the BNLF2a promoter
To question whether the association of Zta with the BNLF2a
promoter is likely to be direct or indirect, we used a pattern-
matching ZRE prediction tool that we previously validated
[33]. This identified five potential ZREs within the BNLF2a
promoter: a cluster of two (distal) and a cluster of three
(proximal) (Fig. S2). The DNA sequences of the five ZREs
were used to generate a position weight matrix that strongly
resembles that found for Zta interaction with DNA in
genome-wide Zta-association studies [18, 34] (Fig. S2). We
then compared the conservation of the BNLF2a promoter
sequence among 92 isolates of EBV (Table S1) to ask
whether these elements are conserved. This revealed a high
degree of conservation of the integrity and location of the
ZREs (ZREs 1–4 100% and ZRE5 86%) (Fig. S2).
Zta interaction with the BNLF2a promoter
To ask whether Zta binds directly to any of the ZREs, we
cloned, expressed and purified a His-tagged GST-Zta fusion
protein (amino acids 168–245), containing the DNA bind-
ing and dimerization region of Zta that has been used previ-
ously to address DNA binding specificity (e.g. [18, 35])
(Fig. 3a, b). IR-labelled double-strand oligonucleotides cor-
responding to each of the five ZREs were used to identify
any interaction of Zta with site binding using electropho-
retic mobility shift assays (Fig. 3c). His-GST protein was
employed as control to identify potential background levels
of DNA retardation, and showed negligible binding to the
ZREs compared to his-GST-Zta. This is shown for ZRE2
in Fig. 3(c). As a further control, a version of ZRE2 with
mutations in the ZRE was constructed and evaluated for
binding by His-GST or His-GST-Zta. Negligible binding
was observed (Fig. 3c). We then questioned the ability of
His-GST-Zta to bind with each of the five BNLF2a ZREs
(Figs 3d and S3). This revealed that his-GST-Zta interacted
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significantly (P0.05) with each of the five ZREs, with the
highest binding observed at ZRE2 (Fig. 3d).
Activation of the BNLF2a promoter through ZREs
In order to determine whether Zta is able to drive activation
of the BNLF2a promoter, we cloned a region around the
transcription start site of the BNLF2a gene into a luciferase
reporter vector (BNLF2a 1–5) (Figs S2, S5 and 4a). We then
introduced this into cells that do not contain EBV: a BL cell
line DG75 [36] and the HeLa epithelial cell line [37]. Co-
transfection with Zta drove induction of BNLF2a 1–5 in
both cell types (Fig. 4b, c). In DG75, Zta increased gene
expression by 38-fold and in HeLa cells Zta increased
expression by 40-fold. In both cases mutation of all five
Fig. 1. Chromatin organization at the BNLF2a promoter is associated with repressive H3K27me3 and H3K9me3 modifications during
latency. Chromatin was isolated from cells harbouring latent EBV, an LCL (a, b), Akata BL (c, d) and Raji BL (e, f) cells. Chromatin pre-
cipitation was undertaken with antibodies specific for the modified histones (H3K27me3 (a, c, e) and H3K9me3 (b, d, f) and their rele-
vant species-specific controls. DNA was eluted from the precipitate and the relative amounts of each of the indicated loci analysed by
Q-PCR relative to the input genomes, and is expressed as a percentage of input binding. In each case the standard deviation is shown
(triplicate measurements). The significance of the difference in binding is shown as **P0.01; ***P 0.001).
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ZREs (BNLF2a Null) lowered baseline activity (Fig. S4a, b)
and caused a dramatic and significant reduction in Zta-
mediated induction (P0.01). In each case there was only a
small (1.3-fold) difference in transfection efficiency (as
monitored by Zta protein expression). These results show
that the majority of Zta-mediated promoter activation
occurs through the ZREs.
Multiple mutations were then introduced into the ZREs
within each of the two Zta ChIP regions, resulting in simul-
taneous mutation of all three ZREs within the proximal Zta
ChIP region and leaving the distal ZREs intact (pBNLF2a 4–
5), or in mutations in both of the distal ZREs, leaving the
proximal region intact (pBNLF2a 1–3) (Fig. 4). In both cases
a small variation in basal promoter activity was detected
Fig. 2. Zta binding to the BNLF2a promoter region. ChIP-Seq data from Akata BL cells undergoing lytic cycle with an antibody that rec-
ognizes chromatin-bound Zta was aligned the EBV genome. The nucleotide position of the EBV genome is shown on the x-axis. The
locations of gene coding regions are shown as arrows, with amplicons used to identify the specific regions by ChIP shown as boxes.
(a). The BNLF2a Locus. (b). The OriLyt region. (c-d). ChIP coupled to Q-PCR analysis of Zta binding was undertaken from chromatin
from cells harbouring lytic EBV: induced Akata BL cells (48 h) (c) and spontaneously lytic LCL#3 cells (d). The Zta ChIP is shown as a
black bar and the control antibody as an open bar. Q-PCR amplification of the indicated loci was undertaken in triplicate. The axes
show percentage binding relative to input chromatin and the error bars indicate the standard deviation. The significance of the differ-
ence in Zta binding to OriLyt flank and Zta is shown (**P0.01).
Almohammed et al., Journal of General Virology
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(Fig. S4). The ability of Zta to activate these promoters was
compared. Mutating the distal Zta ChIP site (BNLF2a 1–3)
resulted in non-significant changes in Zta activation in both
cell types. However, a significant (P0.01) reduction in Zta
activation was found as a result of mutating the proximal
Zta ChIP site in both cell types (BNLF2a 4–5). A 6-fold
(DG75 cells) and 10-fold (HeLa cells) reduction in Zta acti-
vation of BNLF2a 4–5 by Zta was observed. In these experi-
ments, only small differences in transfection efficiency of
between 1.5- and 1.6-fold were evident, as monitored by Zta
protein abundance.
To probe the contributions of the proximal ZREs further,
individual mutations of ZRE1-3 were undertaken (Fig. 5).
As shown in Fig. S4, small changes in basal expression
resulted from these mutations. The ability of Zta to activate
these promoters was assessed in both DG75 (Fig. 5b) and
HeLa cells (Fig. 5c). This revealed that mutating either
ZRE1 (BNLF2a 2–5) or ZRE3 (BNLF2a 1–2 and 4–5) alone
did not have a significant impact on Zta activation, whereas
mutating ZRE2 (BNLF2a 1 and 3–5) resulted in a modest
but significant (P0.01) reduction in Zta activation to
between 50–67% of the wild-type promoter (BNLF2a).
Impact of methylation on the BNLF2a promoter
ZRE1 contains an integral CpG motif (Fig. 6a), which
prompted us to ask whether the site is subject to DNA
methylation in latency. We undertook DNA methylation
sequencing in latent Akata cells. Following bis-sulphite con-
version and desulphonation of genomic DNA, the region
spanning ZRE1 of the BNLF2a promoter was amplified by
PCR and clones captured in a pCDNA3 vector. Individual
analysis of full-length clones that passed quality control
checks showed that ZRE1 was subject to DNA methylation
in a proportion of the clones (20%) (Fig. 6b).
We then asked whether methylation of ZRE1 impacted on
in vitro DNA binding. This was undertaken with the his-
GST-Zta comparing to his-GST as a control (Fig. 6c). This
revealed that methylation of the CpG motif within ZRE1
increased DNA binding significantly (P0.01).
Fig. 3. Interaction between Zta and the BNLF2a ZREs in vitro. (a). A His-tagged GST-Zta expression vector encoding the DNA binding
and dimerization region of Zta was generated. (b). Protein was produced in E. coli and purified using cobalt ion affinity purification.
160 ng of the resulting protein was fractionated on SDS-PAGE together with 160 ng of a his-tagged GST protein and visualized with
Simply Blue stain. (c). 80 ng of His GST and His-GST-Zta proteins were incubated with IR-labelled double-strand oligonucleotide probes
corresponding to BNLF2a ZRE2 or a mutant version of the sequence, and the reactions were then separated on native polyacrylamide
gels using EMSA. The migration of free DNA and bound DNA complexes is shown. (d). Equivalent EMSAs were undertaken with each of
the individual BNLF2a ZREs and the mutant version. The bar graph shows quantitation of binding (% of probe bound) with the standard
deviation from triplicate assays. The statistical significance of binding was compared to the signal generated with His-GST protein
(*P0.05; **P0.01).
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The previous promoter assays were undertaken on non-
methylated DNA. In order to determine whether DNA
methylation had an impact on Zta-mediated activation
of BNLF2a, we undertook in vitro DNA methylation of
BNLF2a 1–5 and control promoters. Methylated and non-
methylated promoters were then introduced into 293T cells
with an expression vector for hisZta (Fig. 7). Little change
in basal activity was observed (Fig. S6c). A modest but sig-
nificant increase (P0.01) in activation by Zta was found
when the BNLF2a 1–5 promoter was subject to DNA meth-
ylation (Fig. 7). In contrast, no activation was observed with
the BNLF2a null promoter in either its methylated or non-
methylated form. This activation is significant ((P0.01).
To probe the relevance of ZRE1 for the enhanced methyla-
tion-dependent Zta activation of BNLF2a, we mutated ZRE
2–5 within the BNLF2a promoter, leaving only ZRE1 intact
(BNLF2a 1) (Fig. 7). Following introduction into 293T cells,
we found little variation in basal expression levels (Fig. S6c)
and little activation of the non-methylated promoter by Zta.
In contrast, we found a three-fold increase (P0.01) in Zta-
driven promoter activity when the BNLF2a 1 promoter was
methylated. In these experiments, the transfection efficiency
differed only by 10%.
DISCUSSION
BNLF2a is an important component of the programme
used by EBV to evade the host immune response during
the EBV lytic cycle and immediately following infection of
B cells [22, 38, 39]. The 60-amino acid protein that it enco-
des blocks TAP presentation of antigens and so renders
Fig. 4. Contribution of Zta-binding regions to BNLF2a promoter activation by Zta. (a). Schematic diagrams of the BNLF2a promoter–
luciferase reporter system. The ZREs are represented by 1–5, with the TATA box and start of the luciferase gene shown. The mutation
of ZREs is represented by an X. (b). The indicated plasmids were introduced into DG75 cells with the his-Zta expression vector (black
box) or a control plasmid (open box). Cells were incubated for 48 h and luciferase activity determined. Zta and actin protein expression
were determined following Western blotting. The statistical significance of the difference in Zta-driven promoter activity between
BNLF2a 1–5 and the mutants is shown **P0.01). (c). The indicated plasmids were introduced into HeLa cells with either the his-Zta
expression vector or a control plasmid. Cells were incubated for 48 h and Zta-driven promoter activity determined as in (b).
Almohammed et al., Journal of General Virology
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cells less susceptible to CD8+ recognition and subsequent
destruction. Two other EBV genes, BILF1 [40–42] and
BALF5 [43–45], have distinct roles in immune evasion
from CD8+ cells. Indeed, within LCLs undergoing the
spontaneous lytic cycle, it was recently shown that knock-
down of the expression of BGLF5 plays only a minor role in
preventing antigen recognition by CD8+ cells, while in
contrast knockdown of the expression of either BNLF2a or
BILF1 prevents antigen recognition [46]. BNLF2a is partic-
ularly influential in preventing recognition of epitopes
derived from Zta and Rta, the earliest proteins expressed
during EBV lytic cycle reactivation, whereas BILF1 protects
against EBV epitopes expressed later during the cycle [46].
Together, these genes reduce CD8+-mediated destruction of
Fig. 5. Contribution of individual proximal Zta-binding elements to BNLF2a promoter activation by Zta. (a). Schematic diagrams of the
mutations introduced into the BNLF2a promoter–luciferase reporter system. (b). The indicated plasmids were introduced into DG75
cells with or without the his-Zta expression vector. Cells were incubated for 48 h and Zta-driven promoter activity determined. Zta and
actin protein expression were determined following Western blotting. The significance of the difference in promoter activity between
BNLF2a ZRE1, 3 and 5 and 1–5 is shown, **P0.01). (c). The indicated plasmids were introduced into HeLa cells with or without the
his-Zta expression vector. Cells were incubated for 48 h and Zta-driven promoter activity determined as in (b).
Almohammed et al., Journal of General Virology
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cells harbouring EBV undergoing replication. If BNLF2a
was not coordinately induced with the start of the EBV lytic
cycle, then its expression and protection from CD8+ cells
would not be coordinated with the onset of the lytic cycle
and the production of infectious virus would be consider-
ably diminished.
The expression of BNLF2a can also be regulated indepen-
dently from EBV gene expression. For example, the pro-
moter controls the expression of transgenes in a lineage-
dependent manner driving high expression in stratifying
epithelia – specifically the tongue, oesophagus and stomach
[47, 48]. In addition, BNLF2a expression has also been
characterized in gastric cancer in EBV-positive cells not
undergoing the full programme of lytic cycle gene expres-
sion [49].
Here we identify BNLF2a as a direct target of the EBV lytic
cycle regulatory protein Zta. This suggests that because Zta
drives the expression of highly immunogenic lytic cycle
proteins, it coordinately drives the expression of a viral
immune evasion gene. This model is based on our discov-
ery of two specific areas of interaction of Zta with the viral
genome within the BNLF2a promoter. We established that
the BNLF2a promoter is highly conserved between viral
isolates, and we identified five conserved Zta-response ele-
ments within this region using in silico analysis and in vitro
DNA binding assays. Critically, we also discovered that
activation of the BNLF2a promoter in cells is dependent on
these ZREs.
By analysing the requirements for Zta-mediated activation
of the BNLF2a promoter in EBV-negative B cells and epithe-
lial cells, we determined that Zta is able to act independently
of other viral proteins to activate BNLF2a. However, the
activation of certain EBV lytic cycle promoters is mediated
by the synergistic action of the viral proteins Zta and Rta
[16]. For example, BMRF1 (pEA-D) shows synergistic acti-
vation by Zta and Rta in certain cell lines but not in others
[50, 51]. We therefore undertook a preliminary analysis to
Fig. 6. Methylation at BNLF2a ZRE1 and impact on Zta DNA binding
(a). The DNA sequence of BNLF2 ZRE1 is shown with the C of each
CpG motif underlined. (b). DNA methylation analysis of the 193 bp
region surrounding the BNLF2a ZRE1 region of EBV is shown for Akata
cell latency. The location and orientation of the BNLF2a coding region
is indicated. Following bisulphite treatment of genomic EBV DNA, and
amplification of the 193 base-pair region, the DNA was sub-cloned
and individual colonies were subject to DNA sequence analysis. The
methylation status of the six CpG motifs within the amplicon was
determined and is shown. Black represents 100% methylation, white
represents non-methylation and grey represents a mixture of methyl-
ated and non-methylated templates. The locations of the TATA box
and ZRE1 are shown for reference. (c). His-GST or His-GST-Zta was
incubated with IR-labelled double-strand oligonucleotide probes corre-
sponding to either BNLF2a ZRE1 or methylated ZRE1, and then the
reactions were separated on native polyacrylamide gels using EMSA.
The bar graph shows quantitation of binding (% of probe bound),
together with the standard deviation from triplicate assays.
Fig. 7. Impact of methylation of ZRE1 on BNLF2a promoter activity (a).
Schematic diagram of mutations that leave only the proximal ZRE
within the BNLF2a promoter. (b). The indicated plasmids were subject
to methylation or not using CpG methyltransferase (M.SssI). These
were introduced into 293T cells with either the his-Zta expression vec-
tor or its control vector. Cells were incubated for 24 h and promoter
activity determined using luciferase assays. The black bars denote the
change in promoter activity when his-Zta is expressed. The statistical
significance of the difference in Zta-driven promoter activity between
non- and methylated BNLF2a 1 is shown (**P0.01). (c). Zta and actin
protein expression was determined following Western blotting.
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determine whether Rta activates or cooperates with Zta to
synergistically activate the BNLF2a promoter, and to date
have found no evidence in support of a role for Rta (data
not show), although we cannot rule out the possibility that
other EBV genes may contribute to regulation of the
BNLF2a promoter.
Although the major impact of Zta-mediated activation of
BNLF2a is driven through the proximal cluster of ZREs, our
mutational analyses revealed that no single ZRE was able to
effect full Zta-mediated activation (data not shown), and
also that no single mutation at a ZRE prevented activation
(Fig. 5). This suggests that more than one Zta binding event
in the proximal promoter region of BNLF2a is required for
BNLF2a activation, but that this can occur at any two of the
three ZREs. This resonates with previous analyses of artifi-
cial promoter constructs. For example, Carey and colleagues
constructed an artificial promoter using basic elements of
the adenovirus E4 promoter abutted to varying numbers of
ZREs [52], whereas Sato and colleagues converted the unre-
sponsive promoter for the cellular collagenase gene into an
Zta target by adding an additional ZRE [53]. As Zta contacts
components of the basal transcriptional machinery (TFIIA
and TFIID) to stabilize transcription complex assembly
[54], these data support a simple model whereby as more
than one molecule of Zta associates with a promoter, the
transcriptional activation increases.
The majority of the EBV genome encoding lytic cycle genes
is subject to DNA methylation at CpG motifs during latency
[11, 29, 55, 56]. The BNLF2a promoter is located between
the promoters LMP2a and LMP1. The broad methylation-
mapping data from this region undertaken by Fernandez
et al. gave a mixed picture, showing promoter-specific DNA
methylation in certain samples of EBV infected cells but not
in others [55]. We decided to ask the specific question of
whether the integral CpG motif within ZRE1 of the BNLF2a
promoter is subject to DNA methylation during EBV
latency in Akata BL cells. Our analysis revealed that DNA
methylation at this CpG motif occurs, but that it is not pres-
ent in all of the genome copies. This is broad in agreement
with Fernandez et al. Importantly, we show that DNA
methylation of CpG within ZRE1 increases the ability of Zta
to interact with ZRE1 and that BNLF2a promoter activation
can be driven through a methylated BNLF2a promoter
when ZRE1 is the only ZRE present. Methylation-depen-
dent Zta activation was less than the 100-fold-change that
has been reported for another EBV promoter (Na); this is
almost fully CpG methylated, contains two CpG-ZREs and
displayed a 100-fold change in Zta mediated activation [57].
However, as BNLF2a is only 20% methylated and has only
one CpG ZRE, this is not surprising. Nonetheless, as ZRE1
is not sufficient to drive full promoter activity, this suggests
that interaction of Zta with more than one ZRE is required
for optimal activation of even the methylated BNLF2a
promoter.
The question of what drives the activation of BNLF2a dur-
ing primary infection of B cells remains unanswered. There
is evidence that Zta RNA is expressed at this stage of the
pre-latency cycle, but no evidence has been found for the
protein [3, 22]. So, while it may be tempting to speculate
that the coincident expression of both Zta and BNLF2a sug-
gests that Zta drives BNLF2a in this situation, there is no
evidence that supports this [3]. It could also be speculated
that cellular transcription factors are responsible for this –
as is likely to be the case in gastric cancer cells [49].
In summary, we have demonstrated that Zta can directly
regulate BNLF2a. However, it is clear that a simple model to
explain the regulation by Zta will not suffice. There is no
single element required to drive full activation – both the
epigenetic status of a single CpG motif with the promoter
and a redundancy in Zta binding sites in the proximal pro-
moter region contribute to Zta-driven promoter activity.
We speculate that the redundancy of ZREs within the pro-
moter provides a fail-safe mechanism for Zta-mediated
BNLF2a activation, ensuring that if access to one ZRE is
blocked, perhaps through interaction with a cellular factor,
Zta interaction with the other two sites will allow it to acti-
vate this important promoter.
METHODS
Cell culture and transfection
Group I EBV-positive Akata BL cells [58], Raji cells [59],
the lymphobalastoid cell lines LCL#3 [32] and GM12878,
and DG75 EBV-negative Burkitt Lymphoma cells [60], were
maintained in RPMI medium supplemented with 10% (v/v)
fetal bovine serum, 100 U of penicillin/ml, 100 µg of strepto-
mycin ml 1 and 2mM L-glutamine (Invitrogen) at 37

C
with 5% (v/v)CO2. For EBV lytic induction of Akata cells
with anti-IgG, cells were seeded in log-phase growth at
5105 cells ml 1. After 24 h, the cells were concentrated to
2106 cells ml 1 and treated with a low dose of 0.125%
(v/v) rabbit anti-human IgG (Dako) or Dulbecco phos-
phate-buffered saline for 48 h. As judged by intracellular
FACS staining, using BZ1 monoclonal antibody the FIX and
PERM Cell Permeabilization Kit and detected using FACS
accuri (Beckton Dickinson), we found that 6% of LCL#3
and 7% of Akata cells were undergoing the lytic cycle (data
not shown).
293T cells (ECACC 12022001) and HeLa cells (ECACC
93021013) were cultured in DMEM medium with 10%
(v/v) fetal bovine serum, 100 U of penicillin ml 1, 100 µg of
streptomycin ml 1 and 2mM L-glutamine (Invitrogen) at
37

C with 5% (v/v) CO2.
Transfections into lymphocytes were undertaken using elec-
troporation with a total of 10 µg of DNA per 107 cells
(50 : 50 expression vector: luciferase reporter) in 300 µl
serum-free media. A 4mm gap-size cuvette was used with a
Genepulser II (BIORAD) set at 250 volts and 975 ohms
capacitance. Cells were harvested 24 h later. Transfections
into adherent cells were undertaken using the non-lipo-
somal effectene reagent (Qiagen). Cells were seeded in
6-well plates at 4105 cells/well. The cells were transfected
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with a total of 1 µg of DNA (500 ng expression vector DNA
with 500 ng reporter vector DNA). Effectene was used at a
ratio of 2.5 µl per µg DNA. Cells were harvested 48 h later,
lysed and processed using the Firefly luciferase assay system
(Promega), with protein concentration determined using a
Bradford or BCA assay (Biorad). Total protein extracts were
also prepared by lysis in SDS-PAGE sample buffer, and Zta
and actin abundance monitored using Western blot analy-
sis. The promoter data were normalized to the total protein
concentration or the actin signal. Promoter activity from
triplicate assays was determined and all experiments were
undertaken on at least two occasions.
Intracellular FACS staining, using BZ1 monoclonal anti-
body and FIX and PERM Cell Permeabilization Kit (Invitro-
gen), was used to determine the population of cells in the
lytic cycle.
Chromatin precipitation
Chromatin was prepared as described previously [19, 61].
Trimethylated histone H3K9 (Abcam ab8898) and trimethyl
histone H3K27 (Abcam ab6002) and species-specific con-
trols were used for the Histone modification chromatin
precipitation assays at the BNLF2a, BRLF1, Cp, Qp and
GAPDH promoters and OriLyt. Goat polyclonal antibody
(sc-17503) against Zta or a control goat antibody (Santa
Cruz Biotechnology) was used for the chromatin precipita-
tion for Zta. The Q-PCR primer sets were published previ-
ously [7, 18, 19].
Western blot
Western blotting. Total cell lysates were resolved on a 12%
(w/v) Bis-Tris Nu- PAGE gel in morpholine propanesul-
fonic acid buffer (Invitrogen). After SDS-PAGE, the pro-
teins were transferred onto nitrocellulose membranes (Santa
Cruz Biotechnology) and incubated with indicated antibod-
ies overnight at 4

C. BZ1 mouse monoclonal antibody to
Zta [14] and a rabbit antibody to beta actin (Sigma) were
used to detect proteins by Western blotting. IR-labelled
anti-mouse and IR-labelled anti-rabbit (Licor) were used as
secondary antibodies and the signals were detected using
infrared detection (Licor Odyssey).
Promoter constructs and plasmids
A cDNA3-based expression vector for Zta that includes a
hexa-histidine tag at the amino terminus (hisZta), together
with its control vector, was used [62]. The BNLF2a pro-
moter was cloned into the pCpGL-basic expression vector
using BamHI and HindIII [63]. The sequence coordinates
for the BNLF2a promoter are 167029–167941 referring to
the Human herpesvirus 4 type 1, complete genome NCBI
Reference Sequence: NC_007605.1. The TATA box is
located between 167062 and 167067. A BamHI site was
introduced at the distal and a HindIII site at the promoter
proximal end using gene synthesis. For each of the ZRE
mutations the ZRE was mutated to CCCCTTT (distal to
proximal). For DNA methylation experiments, the relevant
plasmids were incubated with or without CpG methyltrans-
ferase (M.SssI) in the presence of 160 uM S-adenosylmethio-
nine for 1 h at 37

C as recommended by the manufacturer
(New England Biolabs), then purified using a plasmid mini
clean-up column (Qiagen).
The His-tagged GST-Zta expression vector was generated
by cloning the coding region for Zta (aa 168–245) into the
pOPINJ vector [a gift from Ray Owens (Addgene plasmid #
26045)].
Methylation sequencing
Akata cells were subjected to acyclovir treatment for 48 h to
suppress EBV replication [7]. DNA was prepared using a
Qiamp kit (Qiagen), and 800ng of genomic DNA was subject
to C to T conversion according to the EZ DNA methylation
kit (Zymogen) essentially as described [64]. Nucleotides
166500–166800 of the Akata virus (KC207813.1 Human her-
pesvirus 4 strain Akata), surrounding BNLF2a ZRE1, were
used to design amplification primers using the following
parameters: primer length 24–38, product length 100–350,
Table 1. Oligonucleotides (forward and reverse strands) used as probes for electrophoretic mobility shift assays. The ZREs is shown in bold and
underlined
DNA probe (5’ to 3’) DNA sequence EBV coordinates
NC_007605.1
BNLF2a ZRE1 F ACACCTGTCC TCGCTCA TCTTTCCACA
167099 – 167125BNLF2a ZRE1 R TGTGGAAAGA TGAGCGA GGACAGGTGT
BNLF2a ZRE2 F CACCTGTTGT TGACACA TTCTTTGCGC
167183 – 167209BNLF2a ZRE2 R GCGCAAAGAA TGTGTCA ACAACAGGTG
BNLF2a ZRE3 F CTTTCCATCT TGTGCCA ATACACATTT
167256 – 167282BNLF2a ZRE3 R AAATGTGTAT TGGCACA AGATGGAAAG
BNLF2a ZRE4 F TCACCTTAAC TGGCACA CACTCCCTTA
167593 – 167619BNLF2a ZRE4 R TAAGGGAGTG TGTGCCA GTTAAGGTGA
BNLF2a ZRE5 F TAAGCTACTA TGACTAA CCTTTCTTTA
167692 – 167718BNLF2a ZRE5 R TAAAGAAAGG TTAGTCA TAGTAGCTTA
BNLF2a ZRE1meF ACACCTGTCC TmeCGCTCA TCTTTCCACA
167099 – 167125
BNLF2a ZRE1me R TGTGGAAAGA TGAGmeCGA GGACAGGTGT
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Tm 55–65 and 1 CpG in first 1/3 of primer. The chosen
primers were TTAATTTATGTTAGTAGAGGTAGGAATA
TTTGTTG and AACAAACCRCAAACAAAAAACTACT
ACTCTAACAAAAC. The expected 266 nucleotide amplicon
contained one CpG within the primer and five within the
sequence. BamH1 and EcoR1 cloning sites were added to the
5¢ ends of the primers, together with a six-nucleotide clamp
CCCGGC sequence at the 5¢end. Amplification of 25% of the
converted DNA was undertaken with EpiTaq (TaKaRa) using
a gradient 2.00, 2.25, 2.50, 2.75 and 3.00mM MgCl2, and 40
cycles of 10 s 95

C, 10 s 52.5

C, 30 s 72

C. Amplification was
successfully detected using both 2.75mM and 3.00mMMgCl2
. DNA was isolated using the Qiaquick PCR purification kit
(Qiagen) and subject to restriction digestion with EcoR1 and
BamH1 (NEB). The cloning vector pcDNA3 (Invitrogen) was
also subject to digestion with EcoR1 and BamH1 (NEB). Fol-
lowing ligation and transformation into E. coli, individual col-
onies were isolated and subject to DNA sequencing using the
T7 primer. Clones with a full-length insert quality controlled
(% conversion 95%) using BISMA [65] and the percentage
conversion at each CpG locus were determined. This was plot-
ted graphically using the tool methylation plotter [66].
In vitro DNA binding assays
His-tagged GST-Zta (His-GST-Zta) was expressed in
Rosetta pLysS E. coli in the presence of ampicillin and chlor-
amphenicol. Expression was induced after transferring the
culture to auto-induction media (Overnight Express Instant
TB Medium, Novagen) and incubating at 25

C for 20 h. The
cell pellet was lysed by one round of freeze–thaw followed
by extraction in 50mM Tris HCl pH 7.5, 500mM NaCl,
0.5mM TCEP, 1.5 ulml 1 benzonase and 0.2% Tween. The
soluble protein was loaded onto a Talon cobalt affinity col-
umn (GE) coupled to an AKTA FPLC (GE) and subse-
quently eluted using 50mM Tris HCl pH7.5, 500mM NaCl,
0.5mM TCEP and 150mM imidazole. The eluted protein
was concentrated four-fold using Ultra-4 centrifugal filters
(Amicon) with a 3Kd molecular weight cut-off. Subse-
quently, 500 ul of the sample was loaded onto a GF 75 size
exclusion chromatography column (GE) and eluted using
50mM Tris HCl, 300mM NaCl and 0.5mM TCEP. A
recombinant His-GST protein (Abcam) was compared as
control.
IR-800-labelled double-strand DNA oligonucleotides relat-
ing to each of the five BNLF2a ZREs, a mutant version
of ZRE2 and a CpG-methylated version of ZRE1 were
annealed (IDT) (Table 1). Protein (100 ng) was incubated
with the double-strand oligonucleotides probe (1 nmol) in a
total of 20 µl of gel shift buffer (4% (w/v) glycerol, 1mM
MgCl, 0.5mM EDTA, 5mM DTT, 50mM NaCl and 10mM
Tris-HCl (pH 7.5) for 30min at 20

C. Following separation
on a 6% (w/v) native polyacrylamide gel (0.5XTBE), for 1 h
at 10V cm 1, fluorescent signals were detected in the IR
Odyssey imager (LI-COR) in the 800 channel. Quantitation
was undertaken using Image Studio software (Licor).
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